The Biorasi Project Team were focused on the completion of two critical project milestones which were suddenly put at risk due to the COVID-19 health crisis. Find out how the team were able to keep the project on track in our latest case study.
Biorasi is proud to announce the initiation of the company’s first COVID-19 clinical trial in May 2020. The U.S.-based trial will focus on the treatment for lung injuries caused by the COVID-19 virus.
Dr. Kurt Gehlsen, Chief Scientific Officer and Vice President of Medical and Scientific Affairs, has been appointed to the COVID-19 Rapid Response Funding panel at Science Foundation Ireland (SFI).
To our #sitepartners on the front lines, from all of us at Biorasi, thank you for everything you do to bring critical treatments to patients as we face #COVID19 together.
Digital technology’s presence in the healthcare industry continues to grow, expanding across diagnostic and therapeutic treatments in precision medicine. Biorasi was on-site to witness these advancements and innovations at this year’s Molecular Med Tri-Con.
In observance of Rare Disease Day 2020, Biorasi, LLC held a company-wide event and fundraiser to raise awareness for Angelman Syndrome. The company contributed over $4,000 to the Foundation for Angelman Syndrome Therapeutics. Read more about the highlights of this event >>
The Evolution of Digital Therapeutics and the Need for Clinical Evidence: Lessons Learned from DTx West 2020
With digital therapeutics experiencing an evolution, Biorasi was on hand at DTx West 2020 to highlight the importance of evidence as a differentiator in clinical trials. Read more about our event experience >>
Biorasi, LLC and its Board of Directors are proud to announce the appointment of Chris O’Brien to the position of Chief Executive Officer (CEO). O’Brien will assume day-to-day leadership of Company operations, working closely with the Biorasi leadership team to deliver cutting-edge solutions for clinical research project management.
When stem cell industry innovators from across the globe congregated in Miami at the end of January 2020 to discuss the current state and future expectations of the regenerative medicine industry, Biorasi had more than one reason to be excited about the event. Read the full article for highlights >>
A team from Biorasi was at ASN Kidney Week 2019. Breakthrough research and standout presentations marked this year’s @ASNKidney Week. Check out our report for the full scoop.
A team from Biorasi joined more than 900 leaders from the FDA, NIH and the pharma and bio-pharma industries for the National Organization for Rare Disorders (NORD) & Orphan Products Breakthrough Summit. Throughout two packed days of keynotes, breakout sessions and panel discussions, we gained valuable insight into the most urgent rare disease topics. Read about the a few takeaways from the event in this article.
To execute precision medicine clinical trials, sponsors have adopted a range of new approaches, especially in early-stage studies. Many of these models allow sponsors to recruit more patients and bring drugs to market faster— goals drug developers in all therapeutic areas work toward.